Tempus AI Acquires Personalis in $1.5 Billion Precision Oncology Deal
Tempus AI has agreed to acquire Personalis for $1.5 billion through a stock deal, aiming to enhance its precision oncology capabilities with minimal residual disease (MRD) testing technology. The acquisition is expected to close by early 2027 and includes an option for Tempus to pay up to half in cash.
Topics: acquisition MRD testing precision oncology stock price reaction